Debashree Mukherjea Selected Research

Ototoxicity

1/2022	Transient Receptor Potential Channels and Auditory Functions.
11/2021	Oxidative Stress and Inflammation Caused by Cisplatin Ototoxicity.
1/2021	Effects of Moringa Extract on Aminoglycoside-Induced Hair Cell Death and Organ of Corti Damage.
1/2021	Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss.
1/2021	Ototoxicity of Non-aminoglycoside Antibiotics.
10/2020	Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.
11/2019	Capsaicin Protects Against Cisplatin Ototoxicity by Changing the STAT3/STAT1 Ratio and Activating Cannabinoid (CB2) Receptors in the Cochlea.
5/2019	Mechanisms of Cisplatin-Induced Ototoxicity and Prevention.
1/2019	Local Drug Delivery for Prevention of Hearing Loss.
1/2019	Oral Administration of Caffeine Exacerbates Cisplatin-Induced Hearing Loss.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Debashree Mukherjea Research Topics

Disease

22	Ototoxicity 01/2022 - 04/2007
21	Hearing Loss (Hearing Impairment) 01/2022 - 04/2007
19	Neoplasms (Cancer) 01/2021 - 04/2006
9	Inflammation (Inflammations) 11/2021 - 03/2011
4	Prostatic Neoplasms (Prostate Cancer) 01/2017 - 11/2009
3	Neoplasm Metastasis (Metastasis) 12/2013 - 11/2009
2	Pain (Aches) 01/2022 - 01/2019
2	Noise-Induced Hearing Loss (Acoustic Trauma) 11/2021 - 01/2019
2	Deafness (Deaf Mutism) 01/2021 - 05/2019
2	Peripheral Nervous System Diseases (PNS Diseases) 11/2019 - 01/2019
2	Wounds and Injuries (Trauma) 01/2019 - 05/2011
2	Hypoxia (Hypoxemia) 05/2008 - 05/2003
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2021
1	Hidden Hearing Loss 01/2019
1	Sensorineural Hearing Loss 05/2011
1	Infections 05/2011
1	Melanoma (Melanoma, Malignant) 11/2009

Drug/Important Bio-Agent (IBA)

21	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 04/2007
11	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2021 - 12/2008
7	AntioxidantsIBA 11/2021 - 04/2007
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2006
6	NADPH Oxidases (NAD(P)H oxidase)IBA 04/2016 - 12/2005
5	Protective AgentsIBA 01/2021 - 05/2011
5	Small Interfering RNA (siRNA)IBA 01/2018 - 12/2008
4	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 04/2016
3	Capsaicin (Zostrix)FDA Link 01/2022 - 03/2011
3	Adenosine A1 ReceptorIBA 01/2021 - 04/2016
3	AminoglycosidesIBA 01/2021 - 05/2011
3	N-(1-methyl-2-phenylethyl)adenosine (S-PIA)IBA 01/2019 - 01/2010
2	GTP-Binding Proteins (G-Protein)IBA 01/2021 - 05/2019
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 05/2011
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2021 - 01/2018
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2020 - 01/2017
2	CannabinoidsIBA 11/2019 - 01/2017
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 05/2019 - 01/2017
2	Adenosine (Adenocard)FDA LinkGeneric 01/2019 - 11/2009
2	Etanercept (Enbrel)FDA Link 01/2019 - 01/2019
2	ResveratrolIBA 01/2017 - 01/2012
2	PhenylisopropyladenosineIBA 04/2016 - 01/2010
2	MicroRNAs (MicroRNA)IBA 12/2013 - 01/2012
2	Androgen Receptors (Androgen Receptor)IBA 12/2013 - 01/2012
2	SERPIN-B5 (maspin)IBA 12/2013 - 01/2012
2	RNA (Ribonucleic Acid)IBA 01/2012 - 09/2010
2	Prostaglandins FIBA 05/2008 - 05/2003
1	CationsIBA 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2021
1	MacrolidesIBA 01/2021
1	Erythromycin (Erycette)FDA LinkGeneric 01/2021
1	Gentamicins (Gentamicin)FDA LinkGeneric 01/2021
1	CaspasesIBA 01/2021
1	Clarithromycin (Biaxin)FDA LinkGeneric 01/2021
1	LigandsIBA 01/2021
1	Capreomycin (Capastat)FDA Link 01/2021
1	Vancomycin FDA LinkGeneric 01/2021
1	Azithromycin (Zithromax)FDA LinkGeneric 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Reactive Nitrogen SpeciesIBA 10/2020
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 10/2020
1	PlatinumIBA 10/2020
1	Transcription Factors (Transcription Factor)IBA 11/2019
1	SteroidsIBA 01/2019
1	kenpaulloneIBA 01/2019
1	pifithrinIBA 01/2019
1	AMP-Activated Protein Kinase KinasesIBA 01/2019
1	Caffeine (No Doz)FDA LinkGeneric 01/2019
1	CalciumIBA 01/2019
1	MelatoninIBA 01/2019
1	Methionine (L-Methionine)FDA Link 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	Cyclin-Dependent Kinase 2IBA 01/2019
1	EndocannabinoidsIBA 01/2018
1	Adenosine Triphosphatases (ATPase)IBA 01/2018
1	iodopravadoline (AM 630)IBA 01/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2017
1	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 01/2017
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2017
1	Apoptosis Regulatory ProteinsIBA 01/2017
1	Long Noncoding RNAIBA 01/2017
1	CytokinesIBA 01/2017
1	Investigational DrugsIBA 02/2015
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 12/2013
1	OligonucleotidesIBA 01/2012
1	Protein Isoforms (Isoforms)IBA 09/2010
1	Messenger RNA (mRNA)IBA 01/2010
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 11/2009
1	Purine NucleosidesIBA 11/2009
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 11/2009
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 11/2009
1	Therapeutic UsesIBA 11/2009
1	Mitogen-Activated Protein Kinase 3IBA 04/2006
1	1,3-dipropyl-8-cyclopentylxanthineIBA 04/2006
1	Pertussis ToxinIBA 04/2006

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 01/2018 - 05/2011
3	Oral Administration 11/2019 - 01/2012
3	Therapeutics 01/2019 - 05/2011
3	Injections 04/2016 - 03/2011
1	Cochlear Implantation 11/2021
1	Intratympanic Injection 09/2010
1	Chemoprevention 04/2007